MCL1 and acute myeloid leukemia: Single-agent clinical studies have shown that even the molecule obatoclax, which inhibits both BCL2 as well as its related apoptosis regulator MCL1, is alone not effective in AML, apparently due to the diversity of antiapoptotic mechanisms that AML cells may employ [138].